Biostax Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTAX research report →
Price Chart
About the company
Biostax Corp. is a biopharmaceutical enterprise dedicated to the acquisition, advancement, and commercialization of various pharmaceutical and biotechnology solutions. A pivotal focus lies on Lodonal, their lead investigational drug candidate, designed as a once-daily immune system modulator aimed at managing both human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS).
- CEO
- Noreen Griffin
- IPO
- 2010
- Employees
- 4
- HQ
- Winter Park, FL, US
Get TickerSpark's AI analysis on BTAX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.87K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 67.11%
- ROIC
- 43.69%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,484,950
- Net Income
- $-2,362,647+33.2%
- EPS
- $-0.03+70.0%
- OCF Growth
- +29.9%
- FCF Growth
- +62.3%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.72
- RSI (14)
- 24
- Avg Volume
- 83
No earnings-call transcripts are available for BTAX yet.
- Free Float
- 60.2%
- Shares Outstanding
- 78.71M
- Float Shares
- 47.41M
Our BTAX coverage
Recent articles, reports, and earnings notes.
No research on BTAX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BTAX report →Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration
globenewswire.com · Feb 21
Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception
globenewswire.com · Nov 30
Biostax Announces a Director Appointment of Influential Business Leader Craig Suro
globenewswire.com · Nov 15
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors
globenewswire.com · Nov 2
Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment
globenewswire.com · Oct 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.